Business Context and Reporting Period
Arvinas, Inc. (ARVN) filed a Form 8-K on October 23, 2019, reporting a platform update regarding its clinical development programs. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a Current Report (Item 8.01) focused on clinical trial updates and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material event reported is the release of initial safety, tolerability, and pharmacokinetic data from two ongoing Phase 1 clinical trials:
- ARV-110: Tested in patients with metastatic castration-resistant prostate cancer (mCRPC).
- ARV-471: Tested in patients with locally advanced or metastatic estrogen receptor positive (ER+) / human epidermal growth factor receptor-2 negative (HER2-) breast cancer.
The company presented this data at the 2nd Targeted Protein Degradation Summit on the date of the report.
Guidance, Outlook, and Risks
The filing incorporates a press release and a company presentation by reference but does not contain specific forward-looking guidance, management commentary on financial outlook, or a detailed discussion of risks within the body of the 8-K text. The primary focus is the dissemination of clinical data.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific numerical data regarding safety and pharmacokinetics.
- Examine the company presentation (Exhibit 99.2) for detailed clinical trial results and future timelines.
- Verify the status of the Phase 1 trials for ARV-110 and ARV-471 in subsequent regulatory filings or clinical trial registries.
- Check the company's most recent 10-Q or 10-K for financial position and cash runway, as this 8-K does not provide financial data.